Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback